– ARD2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.
– ClC1=C(C#N)C([H])=C([H])C(=C1[H])OC1([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])(C1(C([H])([H])[H])C([H])([H])[H])N([H])C(C1C([H])=C([H])C(=C([H])C=1[H])N1C([H])([H])C([H])([H])N(C([H])([H])C1([H])[H])C([H])([H])C1([H])C([H])([H])C([H])([H])N(C2C([H])=C([H])C3C(N(C4([H])C(N([H])C(C([H])([H])C4([H])[H])=O)=O)C(C=3C=2[H])=O)=O)C([H])([H])C1([H])[H])=O